List of Figures
Figure 1: Generic Growth Strategies, Global, Revenues of Top Generic Companies ($m), 2008-2009 6
Figure 2: Generic Growth Strategies, Global, Revenues of Top 10 Drugs due for Patent Expiry ($m), 2010-2014 9
Figure 3: Generic Growth Strategies, Global, Total Value of the Drugs to Lose Patent Protection by 2014, by Therapeutic Segment ($bn) 10
Figure 4: Generic Growth Strategies, ANDA Filings, 2001–2009 12
Figure 5: Generic Growth Strategies, ANDA Approvals, 2005–2010 13
Figure 6: Generic Growth Strategies, Generic Market Share in Selected Countries in Off-patent Drugs Market, 2009 14
Figure 7: Generic Growth Strategies, Top Six Biopharmaceuticals of 2009 – High Biosimilars Market Potential 15
Figure 8: Generic Growth Strategies, Patent Applications by Top 10 Pharmaceutical Patent Applicants at US Patent Office, 1995–2008 16
Figure 9: Generic Growth Strategies, Market Share of Leading Generic Companies, 2009 19
Figure 10: Generic Growth Strategies, Revenue of Top Generic Companies ($m), 2008-2009 20
Figure 11: Generic Growth Strategies, Generic Drug Review Process 21
Figure 12: Generic Growth Strategies, ANDA Patent Certification Types and FDA Approval Processes 22
Figure 13: Generic Growth Strategies, Proportion of LCM Projects in the Late-stage Development Pipeline by Therapeutic Area, 2010 23
Figure 14: Generic Growth Strategies, Comparison of CAGR of R&D Expenditure and Growth of Sales Over the Last Five Years for the Top Five Companies, 2003–2008 25
Figure 15: Generic Growth Strategies, the US, Impact Analysis of Changing Regulatory Landscape, 27
Figure 16: Generic Growth Strategies, Acquisitions by Matrix Labs 35
Figure 17: Generic Growth Strategies, Benefits of Marketing Partnership to Watson and Moksha8 40
Figure 18: Generic Growth Strategies, Contribution to Growth, 2009-2014 43
Figure 19: Generic Growth Strategies, Percentage of Out-of-Pocket Healthcare Financing by Country 44
Figure 20: Generic Growth Strategies, Top Strategies to Expand in Pharmerging Markets 46
Figure 21: Generics Growth Strategies, SWOT Analysis for Teva 54
Figure 22: Generics Growth Strategies, SWOT Analysis for Sandoz 55
Figure 23: Generics Growth Strategies, SWOT Analysis for Hospira 56
Figure 24: Generics Growth Strategies, SWOT Analysis for Watson 57
Figure 25: Generics Growth Strategies, SWOT Analysis for Mylan 58
Figure 26: Generics Growth Strategies, SWOT Analysis for Perrigo 59
Figure 27: Generics Growth Strategies, SWOT Analysis for STADA 60
Figure 28: Generics Growth Strategies, SWOT Analysis for PAR 62
Figure 29: Generics Growth Strategies, SWOT Analysis for Apotex 63
Figure 30: Generics Growth Strategies, SWOT Analysis for Lupin 64
Figure 31: Generics Growth Strategies, SWOT Analysis for Actavis 65